

RESEARCH ARTICLE

Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study

Lars Wallentin^{1,2*}, Niclas Eriksson², Maciej Olszowka^{1,2}, Tanja B. Grammer³, Emil Hagström^{1,2}, Claes Held^{1,2}, Marcus E. Kleber⁴, Wolfgang Koenig^{5,6,7}, Winfried März^{4,8,9}, Ralph A. H. Stewart¹⁰, Harvey D. White¹⁰, Mikael Åberg^{11,12}, Agneta Siegbahn^{2,11,12*}

1 Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden, **2** Uppsala Clinical Research Center (UCR), Uppsala University, Uppsala, Sweden, **3** Mannheim Institute of Public Health, Social and Preventive Medicine, Mannheim Medical Faculty, University of Heidelberg, Heidelberg, Germany, **4** Medical Clinic V, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany, **5** Deutsches Herzzentrum München, Technische Universität München, Munich, Germany, **6** DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany, **7** Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany, **8** Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria, **9** SYNLAB Academy, SYNLAB Holding Deutschland GmbH, Mannheim and Augsburg, Germany, **10** Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland, Auckland, New Zealand, **11** Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden, **12** Science for Life Laboratory, Uppsala University, Uppsala, Sweden

* lars.wallentin@ucr.uu.se (LW); Agneta.Siegbahn@medsci.uu.se (AS)



OPEN ACCESS

Citation: Wallentin L, Eriksson N, Olszowka M, Grammer TB, Hagström E, Held C, et al. (2021) Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. *PLoS Med* 18(1): e1003513. <https://doi.org/10.1371/journal.pmed.1003513>

Received: August 27, 2020

Accepted: January 5, 2021

Published: January 13, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pmed.1003513>

Copyright: © 2021 Wallentin et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

Abstract

Background

Circulating biomarkers are associated with the development of coronary heart disease (CHD) and its complications by reflecting pathophysiological pathways and/or organ dysfunction. We explored the associations between 157 cardiovascular (CV) and inflammatory biomarkers and CV death using proximity extension assays (PEA) in patients with chronic CHD.

Methods and findings

The derivation cohort consisted of 605 cases with CV death and 2,788 randomly selected non-cases during 3–5 years follow-up included in the STabilization of Atherosclerotic plaque By Initiation of darapLadlb TherapY (STABILITY) trial between 2008 and 2010. The replication cohort consisted of 245 cases and 1,042 non-cases during 12 years follow-up included in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study between 1997 and 2000. Biomarker levels were measured with conventional immunoassays and/or with the OLINK PEA panels CVD I and Inflammation. Associations with CV death were evaluated by Random Survival Forest (RF) and Cox regression analyses.

Both cohorts had the same median age (65 years) and 20% smokers, while there were slight differences in male sex (82% and 76%), hypertension (70% and 78%), and diabetes (39% and 30%) in the respective STABILITY and LURIC cohorts. The analyses identified 18

Funding: The present study was supported by the Swedish Foundation for Strategic Research (project RB13-0197) to LW and AS, and by Science for Life Laboratory, Uppsala, Sweden (<https://www.scilifelab.se/>). Funding from own institution, Uppsala Clinical Research Center, Uppsala, Sweden (Sweden Organisation number 232100-0024) was given to LW and AS. OLINK Proteomics and Roche Diagnostics provided their respective assays at a reduced cost. GlaxoSmithKline sponsored the main STABILITY trial and the biobanking of the samples but provided no specific support for this sub-study. None of the sponsoring companies had any input on the study design, analyses, interpretation or manuscript preparation. The sponsor was given the opportunity to review and comment on the manuscript. LURIC received funding from the European Union's Horizon 2020 research and innovation programme under the ERA-Net Cofund action N° 727565 (OCTOPUS project) and the German Ministry of Education and Research (grant number 01EA1801A), from the 7th Framework Program (integrated projects AtheroRemo, Grant Agreement number 201668 and RiskyCAD, Project Number 305739) of the European Union, and the Competence Cluster of Nutrition and Cardiovascular Health (nutriCARD) which is funded by the German Federal Ministry of Education and Research (grant number 01EA1411A). None of the sponsors had any input on the study design, analyses, interpretation, the decision to publish, or preparation of the manuscript.

Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: LW reports institutional research grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Merck & Co, Roche Diagnostics; consulting fees from Abbott; holds two patents involving GDF-15, both licensed to Roche Diagnostics. NE and MO report institutional research grants from GlaxoSmithKline. EH reports institutional research grants from AstraZeneca, Amgen, GlaxoSmithKline, Sanofi; consulting fees from Amgen, NovoNordisk, Sanofi; speaker fees from AstraZeneca, Amgen, Boehringer Ingelheim, NovoNordisk, Sanofi; principal investigator fees paid to institution from CSL Behring, Dalcor, Regeneron, Sanofi, The Medicines Company. WK reports research grants from Roche Diagnostics, Beckmann, Singulex, Abbott; other research support from European Research Agency (ERA-CVD); honoraria from Novartis, Pfizer, Sanofi, AstraZeneca, Amgen; expert witness fees from Novartis; consultant/advisory board fees from Novartis, Pfizer, DalCor, Sanofi, Kowa, Amgen. CH

biomarkers with confirmed independent association with CV death by Boruta analyses and statistical significance (all $p < 0.0001$) by Cox regression when adjusted for clinical characteristics in both cohorts. Most prognostic information was carried by N-terminal prohormone of brain natriuretic peptide (NTproBNP), hazard ratio (HR for 1 standard deviation [SD] increase of the log scale of the distribution of the biomarker in the replication cohort) 2.079 (95% confidence interval [CI] 1.799–2.402), and high-sensitivity troponin T (cTnT-hs) HR 1.715 (95% CI 1.491–1.973). The other proteins with independent associations were growth differentiation factor 15 (GDF-15) HR 1.728 (95% CI 1.527–1.955), transmembrane immunoglobulin and mucin domain protein (TIM-1) HR 1.555 (95% CI 1.362–1.775), renin HR 1.501 (95% CI 1.305–1.727), osteoprotegerin (OPG) HR 1.488 (95% CI 1.297–1.708), soluble suppression of tumorigenesis 2 protein (sST2) HR 1.478 (95% CI 1.307–1.672), cystatin-C (Cys-C) HR 1.370 (95% CI 1.243–1.510), tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) HR 1.205 (95% CI 1.131–1.285), carbohydrate antigen 125 (CA-125) HR 1.347 (95% CI 1.226–1.479), brain natriuretic peptide (BNP) HR 1.399 (95% CI 1.255–1.561), interleukin 6 (IL-6) HR 1.478 (95% CI 1.316–1.659), hepatocyte growth factor (HGF) HR 1.259 (95% CI 1.134–1.396), spondin-1 HR 1.295 (95% CI 1.156–1.450), fibroblast growth factor 23 (FGF-23) HR 1.349 (95% CI 1.237–1.472), chitinase-3 like protein 1 (CHI3L1) HR 1.284 (95% CI 1.129–1.461), tumor necrosis factor receptor 1 (TNF-R1) HR 1.486 (95% CI 1.307–1.689), and adrenomedullin (AM) HR 1.750 (95% CI 1.490–2.056).

The study is limited by the differences in design, size, and length of follow-up of the 2 studies and the lack of results from coronary angiograms and follow-up of nonfatal events.

Conclusions

Profiles of levels of multiple plasma proteins might be useful for the identification of different pathophysiological pathways associated with an increased risk of CV death in patients with chronic CHD.

Trial registration

[ClinicalTrials.gov NCT00799903](https://clinicaltrials.gov/ct2/show/study/NCT00799903).

Author summary

Why was this study done?

- There are many reports on associations between biomarkers and outcomes in patients with chronic coronary artery disease (CAD).
- New analytical technologies allow concurrent measurement of hundreds of protein biomarkers in small volumes of plasma.
- The value of multiplex protein analyses has rarely been evaluated in cohorts with adequate numbers of patients and outcome events.

reports Honoraria from Pfizer; consultant/advisory board fees from AstraZeneca, Bayer, Boehringer Ingelheim. MEK reports consulting/speaker fees from Bayer. WM reports grants and personal fees from Siemens Diagnostics, Abbott Diagnostics, AMGEN, Astrazeneca, Sanofi, BASF, Numares AG, employment from SYNLAB Holding Deutschland GmbH. RAHS reports grants and non-financial support from GlaxoSmithKline. HDW reports research grants from Sanofi-Aventis, Dalcour Pharma, NIH, Eisai, Omthera Pharmaceuticals; other support from SAHMRI, ESC, AHA, Sanofi/Regeneron. AS reports institutional research grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Roche Diagnostics, GlaxoSmithKline; consulting fees from Olink Proteomics. TBG and MÅ have nothing to declare.

Abbreviations: AM, adrenomedullin; BMI, body mass index; BNP, brain natriuretic peptide; CA-125, carbohydrate antigen 125; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHD, coronary heart disease; CHI3L1, chitinase-3 like protein 1; CI, confidence interval; CRP-hs, high-sensitivity C-reactive protein; cTnT-hs, high-sensitivity troponin T; CV, cardiovascular; Cys-C, cystatin-C; FGF-23, fibroblast growth factor 23; GDF-15, growth differentiation factor 15; HGF, hepatocyte growth factor; HR, hazard ratio; IL-6, interleukin 6; LDL, low-density lipoprotein; LLOD, lower limit of detection; Lp-PLA₂, lipoprotein associated phospholipase A2; LURIC, Ludwigshafen Risk and Cardiovascular Health; maxstat, maximally selected rank statistics; MI, myocardial infarction; NPX, normalized protein expression; NTproBNP, N-terminal prohormone of brain natriuretic peptide; OPG, osteoprotegerin; PCI, percutaneous coronary intervention; PEA, proximity extension assay; RAS, renin-angiotensin system; RF, Random Survival Forest; SD, standard deviation; sST2, soluble suppression of tumorigenesis 2 protein; STABILITY, STabilization of Atherosclerotic plaque By Initiation of darapladib TherapY; TIM-1, transmembrane immunoglobulin and mucin domain protein; TIMP-1, tissue inhibitor of metalloproteinase-1; TNF-R1, tumor necrosis factor receptor 1; TRAIL-R2, tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

What did the researchers do and find?

- We investigated the associations between the levels of multiple proteins and the occurrence of cardiovascular (CV) death during 3–12 years follow-up of 2 cohorts of 3,393 and 1,287 patients with chronic CAD.
- The biomarkers were measured with the OLINK Proximity Extension Assay (PEA) panels CVD I and Inflammation and/or conventional immunoassays.
- The analyses identified 18 biomarkers with confirmed independent associations with CV death.

What do these findings mean?

- Measurements of levels of plasma protein profiles can be useful for the identification of pathophysiological pathways associated with an increased risk of CV death in patients with chronic coronary heart disease (CHD).
- Measurements of these profiles might be useful for the identification of new treatment targets and to balance different treatments and treatment responses in patients with chronic CHD.

Introduction

Despite revascularization and optimal secondary preventive treatment, chronic coronary heart disease (CHD) is still associated with a substantial cardiovascular (CV) morbidity and mortality [1–3]. Many biomarkers have been shown to be associated with the development and clinical outcomes of CHD. However, only a few biomarkers are recommended in treatment guidelines and routinely used in clinical care [4–8]. Besides indicators of underlying metabolic disease (blood glucose, hemoglobin A1c, and low-density lipoprotein [LDL] cholesterol), the currently generally available prognostic protein biomarkers are those indicating myocardial dysfunction (N-terminal prohormone of brain natriuretic peptide, NTproBNP) [6,7], cardiac necrosis (cardiospecific high-sensitivity troponin T, cTnT-hs), inflammatory activity (high-sensitivity C-reactive protein, CRP-hs) [7], and renal dysfunction (cystatin-C, Cys-C) [4,8]. The rationale for the use of these biomarkers is their associations with underlying disease mechanisms, their incremental prognostic information on CV outcomes in addition to clinical information, and their interaction with treatment effects. There are many reports on associations between a multitude of other biomarkers and the development of CHD. However, their value has rarely been simultaneously evaluated in cohorts with adequate numbers of patients and events and including adjustment both for clinical information and for the established biomarkers.

Newly available analytical technologies allow concurrent measurement of hundreds and even thousands of protein biomarkers in small volumes of plasma [9]. One of these techniques is the proximity extension assay (PEA) technology, allowing simultaneous measurements of 92 proteins in a 1.0- μ l plasma sample by PCR amplification of DNA strands from DNA-labeled antibody pairs [10,11]. In the STabilization of Atherosclerotic plaque By Initiation of darapladib TherapY (STABILITY) trial (ClinicalTrials.gov ID NCT00799903) randomizing 15,828

patients with chronic CHD to darapladib or placebo, without any significant effect on outcomes during 3 to 5 years follow-up, we obtained plasma aliquots from all patients at baseline [12,13]. Our previous reports from this program have verified the independent prognostic importance of NTproBNP, cTnT-hs, CRP-hs, interleukin 6 (IL-6), growth differentiation factor 15 (GDF-15), and lipoprotein associated phospholipase A2 (Lp-PLA₂) [14–17]. The primary aim of the present multimarker substudy was to investigate if additional biomarkers were associated with CV death in patients with chronic CHD. The findings were replicated in an observational cohort with chronic CHD followed for 12 years in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study [16].

Methods

Patients and study cohorts

The initial cohort of the present study was a substudy of the previously published international STABILITY trial, which compared darapladib, a selective inhibitor of Lp-PLA₂, with placebo concerning the occurrence of CV events in 15,828 patients with chronic CHD out of whom 14,124 provided blood samples for the biomarker substudy [12,13]. The patients were recruited in 663 centers in 39 countries from December 2008 to April 2010. The patients were followed from 3 to 5 years with a median of 3.7 years. Patients were eligible if they had chronic CHD documented by prior myocardial infarction (MI) (>1 month), prior percutaneous coronary intervention (PCI) (>1 month), or prior coronary artery bypass grafting (CABG) (>3 months) or multivessel coronary artery disease (CAD) at a coronary angiogram. Outcomes were ascertained by regular follow-up visits until the end of the trial, and all study endpoints were centrally adjudicated. There were no significant effects of the randomized treatment on the outcomes. The present multimarker substudy was based on an unstratified case-cohort design consisting of a random sample from the full cohort, which was enriched with all patients suffering CV outcomes in the total biomarker cohort leading to a comparison between 2,788 patients without CV death and 605 patients with CV death.

The LURIC prospective observational study was used for replication. The LURIC study included 3,316 patients scheduled for coronary angiography between July 1997 and January 2000. Patients presenting with unstable angina, non-ST elevation MI, ST-elevation MI, and severe diseases other than chronic CHD were excluded in the current study. The patients were followed for 12 years concerning vital status, and cause of death was established by death certificates. In these analyses, 245 patients with CV death during the 12 years follow-up constituted the cases and 1,042 patients without this event the non-cases.

Ethics statement

Both studies were approved by the relevant institutional review boards and performed in accordance with the Declaration of Helsinki, and all patients provided written informed consent [16].

Biochemical analyses

Venous blood samples were obtained at inclusion in the morning after 9 hours of fasting. EDTA plasma aliquots were stored at -80°C until biochemical analyses. Established biochemical assays for NTproBNP, cTnT-hs, CRP-hs, IL-6, GDF-15, and Lp-PLA₂ were centrally performed as previously published [12–17]. The proteomic analyses were performed at the Clinical Biomarkers Facility, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, without information on any other data. We used the OLINK Proteomics PEA technology,

which is based on pairs of antibodies equipped with DNA single-strand oligonucleotide reporter molecules. Each OLINK PEA panel contains 96 oligonucleotide-labeled antibody probe pairs that bind to their respective target if present in the sample [9,10]. Target binding by both antibodies in a pair generates double-stranded DNA amplicons, which are quantified using a Fluidigm BioMark™ HD real-time PCR platform. The analyses were run using the recommended internal control, and inter-plate variability was adjusted by intensity normalization. The resulting relative values, normalized protein expression (NPX) data, were log₂ transformed. In the logarithmic phase of the curve, 1 increase of the NPX value corresponds to a doubling of the protein content, and a high NPX value corresponds to a high protein concentration. The signal specificity is exceptionally high, as binding by the 2 protein specific antibodies in close proximity is required to produce a signal. PEA assays have shown high reproducibility and repeatability with mean intra-assay and inter-assay coefficients of variation around 8% and 12%, respectively; average inter-site variation has been reported at 15% [9]. In the STABILITY cohort, we used the OLINK Proteomics Multiplex CVD I^{96×96} panel and the OLINK Proteomics Multiplex Inflammation^{96×96} panel, whereby the concentrations of a total of 157 proteins related to CV disease and inflammation were simultaneously measured. In the LURIC cohort, we used only the OLINK Proteomics Multiplex CVD I^{96×96} panel as only 4 of the 28 biomarkers with confirmed association to CV death in the STABILITY cohort were in the Inflammation panel and none among the 13 most important. The protein markers included in the CVD I and Inflammation panels are given in [S1 Table](#).

Statistics

The PEA CVD I and Inflammation panels together measured the concentrations of 184 proteins, of which 27 were included in both panels. For 32 proteins, more than 10% of patient samples had levels below the lower limit of detection (LLOD). We chose to include as many proteins as possible by excluding only the 3 proteins for which more than 99.5% of all patient samples had values below LLOD, leaving 154 unique proteins for the statistical analyses ([S2A Table](#)). Values below LLOD were imputed with LLOD/2.

Baseline characteristics, established biomarkers, and PEA biomarkers were presented and compared by conventional statistics: chi-squared and Wilcoxon tests for discrete and continuous variables, respectively. Correlations between conventionally measured biomarkers and PEA biomarkers were presented as Spearman correlation coefficients using NPX data for PEA biomarkers and logarithmic transformation of biomarker concentrations measured with other assays. Because of the large number of observations, most correlation coefficients were expected to be statistically significant, and only correlation coefficients above 0.29 explaining at least 9% of the variability were considered relevant. Correlations between PEA biomarkers present on both CVD I and Inflammation panels were calculated using Pearson correlation coefficients.

Random Survival Forest (RF) analyses were performed to provide an unbiased grading of the prognostic importance of all variables including all clinical characteristics, PEA levels, and levels of other biomarkers. As the variable importance calculated by the RF could theoretically give identical results in a sample of 1,000 to 100,000 individuals, a Boruta analysis was used to confirm which of the variables in the RF analysis had a larger than random association with outcomes [18]. In short, the Boruta analysis performs multiple runs of RF comparing all variables to random variables, which are shuffled copies of the original variables. Variables performing better than the maximum random variable importance are classified as confirmed, variables performing worse are rejected, and variables that cannot be confirmed or rejected are classified as tentative. Biomarkers with confirmed associations at RF-Boruta analyses in both

studies were considered to have an externally validated association with CV death. In both RF and Boruta analyses, the following settings were used: variable importance mode = permutation, mtry (randomly selected number of variables to possibly split in each node) = square root of total number of variables, minimal node size = 3, and splitrule = maxstat (maximally selected rank statistics). In the RF, we used 10,000 trees, and in the Boruta analysis, the number of trees was lowered to 1,000 due to performance issues.

The linear associations between the biomarkers and CV death were also investigated by Cox regression analyses including both clinical characteristics, established standard immunoassays, and PEA biomarkers and were presented as Forest plots. According to the study design, the Cox regression analyses included the sampling weights for each outcome and were estimated using a robust sandwich estimator. The Cox regression analyses were performed unadjusted using a predefined model [12–17] adjusting for baseline characteristics (age, sex, body mass index (BMI), current smoking, hypertension, diabetes mellitus, previous MI, previous coronary revascularization, previous stroke, previous peripheral artery disease, and randomized treatment) and adjusting also for renal function (Cys-C) and the established markers of CV risk (NTproBNP and cTnT-hs). The incremental discriminative value of each biomarker was illustrated by the C-index. If conventional as well as PEA measurements were available, only the conventional result was included in the RF and Cox analyses, considering its quantitative measurement and larger dynamic range. In the RF, Boruta, and Cox regression analyses, missing values (other than protein values below LLOD) were imputed once using the mice package for R [19,20]. The statistical analyses were predefined in a statistical analysis plan for the STABILITY PEA study in March 2017, and thereafter for replication also applied for the LURIC PEA study.

Results

PEA measurements

The PEA measurements had acceptable reproducibility with Pearson correlation coefficients 0.80 to 0.97 for 23 and a standard deviation of the difference in levels of 0.18 to 0.31 for 17 of the 27 proteins that were included in both the CVD I and Inflammation panels (S4A Table). The PEA measurements also had adequate accuracy with close correlations with conventional immunoassays with Spearman correlation coefficients of 0.87 for NTproBNP, 0.85 for GDF-15, and 0.88 for IL-6 and similar associations to CV death with both methods (S4B Table). The Spearman correlations between the immunoassays of the cardiorenal and inflammatory biomarkers Cys-C, NTproBNP, cTnT-hs, GDF-15, and IL-6 and the PEA biomarkers in the STABILITY cohort are shown in S5 Table for those PEA biomarkers with any correlation coefficient >0.29. There were significant and relevant correlations between many biomarkers, prompting multivariable adjustments when evaluating the importance of associations between biomarker levels and clinical outcomes.

STABILITY population

Baseline characteristics in the random sample and in the total STABILITY trial were almost identical (S3 Table). The baseline characteristics and the levels of established CV biomarkers in the group with CV death and in the random sample without any such event are shown in Table 1.

The crude bivariate comparison of the 154 biomarkers between the 605 cases and 2,788 non-cases showed significant differences with $p < 0.0001$ for 87 biomarkers (S6A Table). An unbiased selection of variables (biomarkers as well as clinical variables) with linear or nonlinear associations with CV death occurrence was performed by RF analyses. Prognostic

Table 1. Baseline characteristics and levels of established biomarkers in patients with and without CV death in the STABILITY and LURIC.

Baseline characteristics	STABILITY			LURIC		
	No event (N = 2,788)	CV death (N = 605)	p-value	No event (N = 1,042)	CV death (N = 245)	p-value
Age (years)	59/65/71	61/69/75	<0.001	57/63/70	63/69/74	<0.001
Sex: Male	82% (2,283)	83% (502)	0.527	75% (779)	80% (196)	0.085
Smoker	20% (549)	22% (130)	0.299	16% (169)	16% (40)	0.021 ^a
Hypertension	70% (1,950)	78% (470)	<0.001	76% (794)	82% (200)	0.068
Diabetes	38% (1,054)	53% (318)	<0.001	26% (225)	43% (106)	<0.001
Prior MI	59% (1,644)	67% (405)	<0.001	43% (444)	55% (134)	<0.001
Prior PCI or CABG	76% (2,114)	61% (369)	<0.001	37% (382)	40% (97)	0.403
Prior stroke or TIA	9% (241)	11% (67)	0.059	7% (70)	19% (47)	<0.001
Prior PAD	8% (215)	17% (105)	<0.001	10% (102)	19% (47)	<0.001
Randomized to darapladib	52% (1,437)	48% (290)	0.108			
Medications at baseline						
Aspirin	92% (2,572)	90% (542)	0.031	74% (766)	72% (176)	0.594
P ₂ Y ₁₂ inhibitors	34% (936)	30% (183)	0.115			
Beta-blockers	79% (2,203)	81% (488)	0.366	65% (675)	52% (127)	<0.001
Statin treatment	97% (2,709)	98% (594)	0.159	52% (546)	48% (118)	0.233
ACE or angiotensin receptor inhibitors	76% (2,124)	80% (483)	0.054	53% (554)	70% (172)	<0.001
Established biomarkers						
GFR by CKD-EPI (ml/min)	62/74/86	52/66/81	<0.001	76/88/97	61/79/93	<0.001
Cys-C (mg/L)	0.86/1.00/1.16	0.98/1.18/1.44	<0.001	0.81/0.90/1.04	0.89/1.03/1.27	<0.001
NTproBNP (ng/L)	85/174/353	250/573/1,269	<0.001	94/230/616	292/762/1927	<0.001
cTnT-hs (ng/L)	6.3/9.3/14.1	10.8/16.4/26.0	<0.001	5.00/8.41/14.85	9.66/17.00/30.98	<0.001
CRP-hs (mg/L)	0.6/1.3/3.0	0.9/1.8/4.7	<0.001	1.120/2.410/5.805	1.590/4.420/10.200	<0.001
IL-6 (ng/L)	1.4/2.1/3.2	1.9/3.0/4.9	<0.001			
GDF-15 (ng/L)	91.4/1,243/1,766	1,231/1,755/2,738	<0.001			
Lp-PLA ₂ (μmol/min/L)	144.3/171.5/201.7	150.0/183.6/219.2	<0.001			
LDL cholesterol (mmol/L)	1.64/2.10/2.61	1.65/2.20/2.91	0.015	2.43/2.98/3.60	2.51/2.95/3.57	0.909
HDL cholesterol (mmol/L)	1.00/1.18/1.40	0.97/1.16/1.37	0.149	0.83/0.98/1.14	0.80/0.96/1.19	0.221
Triglycerides (mmol/L)	1.09/1.50/2.08	1.04/1.48/2.08	0.359	1.27/1.68/2.29	1.16/1.58/2.23	0.095
Hemoglobin (g/L)	134/144/152	130/141/152	0.001	131/141/150	126/137/148	0.003
WBC count (10 ⁹ /L)	5.4/6.5/7.7	6.0/7.2/8.3	<0.001	5.59/6.60/7.90	5.80/6.88/8.40	0.022

Categorical variables are reported as % (n), whereas continuous variables are reported by the percentiles 25th/50th/75th.

CKD-EPI was calculated based on creatinine, age, and gender.

a Comparison also includes the category prior smoker, which were 50% (517) for non-cases and 58% (143) for cases in the LURIC data. ACE, angiotensin converting enzyme; CABG, coronary artery bypass grafting; CKD-EPI, chronic kidney disease epidemiology collaboration; CRP-hs, high-sensitivity C-reactive protein; cTnT-hs, high-sensitivity troponin T; CV, cardiovascular; Cys-C, cystatin-C; GDF-15, growth differentiation factor 15; GFR, glomerular filtration rate; HDL, high-density lipoprotein; IL-6, interleukin 6; LDL, low-density lipoprotein; Lp-PLA₂, lipoprotein associated phospholipase A2; LURIC, Ludwigshafen Risk and Cardiovascular Health; MI, myocardial infarction; NTproBNP, N-terminal prohormone of brain natriuretic peptide; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STABILITY, Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY; TIA, transient ischemic attack; WBC, white blood cell.

<https://doi.org/10.1371/journal.pmed.1003513.t001>




Fig 1. Variable importance in the STABILITY cohort. Boruta analysis in the STABILITY cohort of the significance of variable importance for CV death in the RF analysis, including clinical variables as well as established and PEA biomarkers. Values are NPX values for the PEA biomarkers and log₂ for the ng/L levels of NTproBNP, cTnT-hs, IL-6, GDF-15, Cys-C, CRP-hs, Lp-PLA₂, and WBC measured by conventional quantitative assays. Color coding according to the Boruta analysis result: green = confirmed, yellow = tentative, and red = rejected. CRP-hs, high-sensitivity C-reactive protein; cTnT-hs, high-sensitivity troponin T; CV, cardiovascular; Cys-C, cystatin-C; GDF-15, growth differentiation factor 15; IL-6, interleukin 6; Lp-PLA₂, lipoprotein associated phospholipase A₂; NPX, normalized protein expression; NTproBNP, N-terminal prohormone of brain natriuretic peptide; PEA, proximity extension assay; RF, Random Survival Forest; STABILITY, Stabilization of Atherosclerotic plaque By Initiation of darapLadIb Therapy; WBC, white blood cell.

<https://doi.org/10.1371/journal.pmed.1003513.g001>

importance is presented in [S1A Fig](#). According to the corresponding Boruta analysis, 28 biomarkers had confirmed importance for the selection of patients with CV death ([Fig 1](#), [Table 2](#)). Linear associations of biomarker levels with CV death were investigated by unadjusted ([S2A Fig](#)) and adjusted Cox regression analyses ([Fig 2](#), [Table 2](#)). According to these analyses, NTproBNP and cTnT-hs carried most of the prognostic information, and addition of any of the other biomarkers increased C-index by less than 0.01 ([Table 2](#)).

Replication population

The baseline characteristics of the LURIC population is shown in [Table 1](#). In this cohort, the RF and Boruta analyses identified 21 biomarkers of confirmed importance for CV death, of which 18 also had been identified in the STABILITY cohort ([Figs 3 and 4](#), [S1B and S2B Figs](#), [S6B Table](#)). Also, in the LURIC cohort, the 2 strongest prognostic biomarkers were NTproBNP and cTnT-hs. At the next level of importance, another 16 biomarkers of prognostic importance were verified, in descending order: GDF-15, adrenomedullin (AM), osteoprotegerin (OPG), transmembrane immunoglobulin and mucin domain protein (TIM-1), renin (REN), Cys-C, tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), soluble suppression of tumorigenesis 2 protein (sST2), BNP, hepatocyte growth factor (HGF), IL-6, carbohydrate antigen 125 (CA-125), spondin 1 (SPON-1), tumor necrosis factor receptor 1 (TNF-R1), fibroblast growth factor 23 (FGF-23), and chitinase-3 like protein 1 (CHI3L1). When investigating these biomarkers by Cox regression analyses, adjusting for renal function (Cys-C) and the strongest prognostic biomarkers NTproBNP and cTnT-hs, only 1 biomarker (REN) increased the C-index by more than 0.01 ([Table 3](#), [Fig 4](#)).

Table 2. Associations between CV death and biomarkers RF analysis in the STABILITY cohort including biomarkers with confirmed importance according to the Boruta procedure and also showing results from the Cox regression analyses.

	Order RF	By SD	Adjusted by clinical variables ^a			Also for Cys-C+NTproBNP+cTnT-hs ^b				
			HR	CI	C-index	p-value	HR	CI	C-index	p-value
NTproBNP	1	1.74	2.846	(2.524–3.209)	0.802	<0.001	2.348	(2.051–2.689)	0.808	<0.001
Troponin-T	2	0.96	2.048	(1.865–2.248)	0.766	<0.001	1.483	(1.323–1.663)	0.808	<0.001
BNP	3	1.84	2.292	(2.058–2.554)	0.765	<0.001	1.089	(0.910–1.302)	0.808	0.352
VEGF-D	4	0.53	1.933	(1.673–2.234)	0.735	<0.001	1.261	(1.089–1.459)	0.810	0.002
TRAIL-R2	5	0.49	1.255	(1.149–1.370)	0.722	<0.001	1.250	(1.171–1.334)	0.811	<0.001
Cys-C	6	0.38	1.663	(1.508–1.834)	0.735	<0.001	0.983	(0.869–1.112)	0.808	0.784
SPON1	7	0.31	1.845	(1.625–2.095)	0.733	<0.001	1.247	(1.090–1.427)	0.811	0.001
U-PAR	8	0.35	1.565	(1.394–1.756)	0.721	<0.001	1.088	(0.946–1.252)	0.809	0.238
GDF-15	9	0.79	1.726	(1.547–1.925)	0.731	<0.001	1.264	(1.100–1.452)	0.811	<0.001
IL-6	10	0.95	1.524	(1.396–1.664)	0.726	<0.001	1.133	(1.021–1.257)	0.811	0.018
HGF	12	0.45	1.550	(1.410–1.704)	0.721	<0.001	1.263	(1.137–1.404)	0.813	<0.001
OPG	13	0.40	1.525	(1.360–1.710)	0.715	<0.001	1.290	(1.139–1.460)	0.811	<0.001
TGF-alpha	14	0.44	1.288	(1.201–1.381)	0.713	<0.001	1.073	(0.964–1.195)	0.808	0.198
TNF-R1	15	0.40	1.514	(1.356–1.692)	0.715	<0.001	1.012	(0.864–1.185)	0.808	0.884
MMP-12	16	0.74	1.428	(1.289–1.581)	0.711	<0.001	1.098	(0.973–1.238)	0.810	0.129
CH3L1	18	1.17	1.432	(1.314–1.561)	0.716	<0.001	1.180	(1.065–1.307)	0.811	0.002
LIF-R	19	0.28	1.472	(1.304–1.660)	0.713	<0.001	1.102	(0.970–1.252)	0.808	0.137
FGF-23	20	0.75	1.344	(1.242–1.454)	0.716	<0.001	1.132	(1.034–1.239)	0.810	0.007
CCL25	22	0.64	1.399	(1.244–1.573)	0.710	<0.001	1.157	(1.024–1.308)	0.810	0.020
WBC (lab log2)	23	0.38	1.336	(1.211–1.473)	0.711	<0.001	1.155	(1.036–1.289)	0.811	0.009
CCL28	24	0.44	1.194	(1.103–1.293)	0.701	<0.001	1.077	(0.966–1.202)	0.809	0.181
LOX-1	25	0.76	1.184	(1.090–1.285)	0.702	<0.001	1.113	(1.015–1.220)	0.810	0.022
Lp-PLA ₂ (lab log2)	27	0.43	1.287	(1.160–1.428)	0.699	<0.001	1.159	(1.039–1.292)	0.810	0.008
TIM	28	0.91	1.395	(1.272–1.530)	0.713	<0.001	1.162	(1.049–1.287)	0.810	0.004
sST2	29	0.59	1.509	(1.354–1.682)	0.714	<0.001	1.199	(1.079–1.332)	0.812	<0.001
CA-125	31	0.92	1.466	(1.318–1.629)	0.713	<0.001	1.155	(1.047–1.275)	0.809	0.004
REN	36	0.99	1.237	(1.110–1.378)	0.701	<0.001	1.209	(1.089–1.343)	0.811	<0.001
GH	37	2.00	1.322	(1.201–1.455)	0.703	<0.001	1.101	(0.989–1.225)	0.808	0.079

Values are NPX values (log₂ scale) for the PEA biomarkers and log₂ for the levels of NTproBNP, Troponin T-hs, IL-6, GDF-15, Cys-C, CRP-hs, Lp-PLA₂ activity, and WBC measured by conventional quantitative assays. SD, standard deviation. HRs and 95% CI are calculated for increase of 1 SD. HR and C-indices are calculated after adjustment for clinical variables as above and also after adjustment for the biomarkers NTproBNP, cTnT-hs, and Cys-C.

a Clinical variable adjustment includes the variables age, sex, BMI, smoking, hypertension, diabetes mellitus, prior MI, prior PCI or CABG, prior stroke/TIA, prior PAD, and randomized treatment. b Adjustment also for Cys-C, NTproBNP, and cTnT-hs affects the HRs and C-indices of all variables. This leads to all C-indices having a minimal level of 0.808, i.e., the C-index for clinical variables and the 3 biomarkers Cys-C, NTproBNP, and cTnT-hs. The incremental discriminatory value of adding any additional biomarker can then be estimated by subtracting the corresponding C-index with 0.808, e.g., for GDF-15 the increment of the C-index is 0.003.

BMI, body mass index; BNP, brain natriuretic peptide; CA-125, carbohydrate antigen 125; CABG, coronary artery bypass grafting; CCL25, chemokine ligand 25; CCL28, chemokine ligand 28; CH3L1, chitinase-3 like protein 1; CI, confidence interval; cTnT-hs, high-sensitivity troponin T; CV, cardiovascular; Cys-C, cystatin-C; FGF23, fibroblast growth factor 23; GDF-15, growth differentiation factor 15; HGF, hepatocyte growth factor; GH, growth hormone; HR, hazard ratio; IL-6, interleukin 6; LIF-R, leukemia inhibitory factor receptor; LOX1, lectin-like oxidized LDL receptor 1; Lp-PLA₂, lipoprotein associated phospholipase A2; MI, myocardial infarction; MMP-12, matrix metalloproteinase-12; NPX, normalized protein expression; NTproBNP, N-terminal prohormone of brain natriuretic peptide; OPG, osteoprotegerin; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PEA, proximity extension assay; REN, renin; RF, Random Survival Forest; SD, standard deviation; SPON1, Spondin 1; sST2, soluble suppression of tumorigenesis 2 protein; STABILITY, STabilization of Atherosclerotic plaque By Initiation of darapladib Therapy; TGF-alpha, transforming growth factor alpha; TIA, transient ischemic attack; TIM, transmembrane immunoglobulin and mucin domain protein; TNF-R1, tumor necrosis factor receptor 1; TRAIL-R2, tumor necrosis factor-related apoptosis-inducing ligand receptor 2; U-PAR, urokinase plasminogen activator receptor; VEGF-D, vascular endothelial growth factor D; WBC, white blood cell.

<https://doi.org/10.1371/journal.pmed.1003513.t002>

Variable	By SD	N	HR [95% CI]	p-value
NT-Pro-BNP (lab log2)	1.74	3393	2.85 [2.52, 3.21]	1.56e-65
BNP	1.84	3393	2.29 [2.06, 2.56]	2.50e-51
Troponin-T (lab log2)	0.96	3393	1.06 [1.01, 1.11]	3.11e-06
VEGF-D	0.53	3393	1.93 [1.67, 2.23]	3.99e-19
SFRP1	0.31	3393	1.85 [1.67, 2.10]	3.89e-18
GDF-15 (lab log2)	0.79	3393	1.73 [1.55, 1.93]	1.43e-22
CABP1 (lab log2)	0.38	3393	1.66 [1.41, 1.92]	3.67e-23
U-PAR	0.35	3393	1.56 [1.39, 1.76]	2.89e-16
RGE	0.45	3393	1.41 [1.20, 1.64]	1.11e-18
OPG	0.40	3393	1.53 [1.36, 1.71]	4.75e-13
IL-6 (lab log2)	0.35	3393	1.22 [1.00, 1.48]	4.00e-21
TNF-R1	0.40	3393	1.21 [1.06, 1.39]	2.01e-13
RAGE	0.49	3393	1.43 [1.27, 1.61]	1.11e-18
LIF-R	0.28	3393	1.47 [1.30, 1.66]	3.49e-10
PCP	0.37	3393	1.47 [1.32, 1.64]	1.89e-12
CD125	0.92	3393	1.47 [1.32, 1.64]	1.89e-12
CD40	0.46	3393	1.43 [1.27, 1.57]	3.35e-15
CTSL	1.17	3393	1.30 [1.15, 1.46]	5.72e-16
MMP-12	0.74	3393	1.43 [1.29, 1.58]	7.79e-12
TNF-R2	0.53	3393	1.41 [1.26, 1.56]	9.74e-12
CD25	0.91	3393	1.40 [1.27, 1.53]	1.89e-02
TIM	0.91	3393	1.40 [1.27, 1.53]	1.89e-02
HK1	0.61	3393	1.38 [1.27, 1.49]	1.40e-04
OCL23	0.51	3393	1.37 [1.23, 1.51]	1.70e-09
IL-15RA	0.41	3393	1.37 [1.22, 1.54]	1.75e-07
IL27A	0.40	3393	1.35 [1.21, 1.52]	1.71e-07
ESM-1	0.44	3393	1.36 [1.22, 1.51]	2.34e-08
OSF-1	0.27	3393	1.35 [1.21, 1.52]	1.71e-07
HSCR1 (lab log2)	1.70	3393	1.35 [1.21, 1.49]	9.13e-10
CSFB	0.97	3393	1.35 [1.21, 1.49]	7.27e-10
FGF-23	0.75	3393	1.34 [1.21, 1.48]	2.33e-03
OST5	0.54	3393	1.34 [1.21, 1.48]	6.34e-09
WBC (lab log2)	0.38	3393	1.21 [1.07, 1.37]	0.16e-06
CXCL5	0.86	3393	1.33 [1.22, 1.46]	7.42e-10
CHI	0.55	3393	1.32 [1.21, 1.44]	7.91e-10
TNFRSF9	0.55	3393	1.32 [1.21, 1.44]	7.91e-10
Beta-NGF	0.68	3393	1.31 [1.18, 1.45]	1.85e-09
CXCL6	0.54	3393	1.31 [1.20, 1.43]	1.04e-09
SLAMF1	0.54	3393	1.31 [1.20, 1.43]	1.04e-09
PTX3	0.55	3393	1.30 [1.18, 1.44]	1.85e-09
ODC1	0.63	3393	1.30 [1.18, 1.42]	2.08e-08
TGF-alpha	0.44	3393	1.29 [1.16, 1.43]	1.97e-06
IL-1L1 (lab log2)	0.43	3393	1.29 [1.16, 1.43]	1.97e-06
VEGF-A	0.39	3393	1.28 [1.17, 1.39]	1.85e-08
EN-RAGE	0.49	3393	1.28 [1.17, 1.39]	1.85e-08
OSM	0.06	3393	1.26 [1.17, 1.39]	5.96e-08
RETN	0.89	3393	1.26 [1.15, 1.38]	1.06e-06
TRAIL-R2	0.64	3393	1.26 [1.15, 1.38]	1.16e-05
FCCAM1	0.41	3393	1.26 [1.15, 1.37]	4.11e-07
IL-18R1	0.44	3393	1.24 [1.12, 1.36]	5.18e-05
REN	0.99	3393	1.24 [1.13, 1.36]	6.31e-06
uPA	0.38	3393	1.23 [1.11, 1.37]	7.52e-05
GaI-3	0.42	3393	1.23 [1.10, 1.38]	3.01e-04
AGRP	0.32	3393	1.23 [1.10, 1.38]	3.01e-04
CXCL16	0.32	3393	1.23 [1.10, 1.38]	3.01e-04
TIE2	0.30	3393	1.21 [1.09, 1.34]	4.40e-02
MMP-3	0.68	3393	1.23 [1.11, 1.36]	6.11e-05
PD-L1	0.48	3393	1.21 [1.09, 1.34]	3.51e-04
CCL20	0.92	3393	1.20 [1.11, 1.30]	5.40e-06
IL-8	0.38	3393	1.20 [1.09, 1.29]	4.20e-02
OCL28	0.44	3393	1.19 [1.10, 1.29]	1.16e-05
MCP-3	0.79	3393	1.19 [1.06, 1.32]	6.94e-03
GDNF	0.47	3393	1.19 [1.06, 1.32]	2.44e-03
CXCL10	0.89	3393	1.18 [1.09, 1.29]	5.78e-05
LOX-1	0.76	3393	1.18 [1.09, 1.29]	5.78e-05
MDM-10	0.39	3393	1.18 [1.08, 1.30]	4.41e-04
IL-10RB	0.47	3393	1.18 [1.06, 1.32]	2.37e-03
CCL3	0.87	3393	1.18 [1.11, 1.26]	5.98e-07
CXCL11	0.97	3393	1.17 [1.08, 1.27]	1.73e-03
KLK6	0.46	3393	1.17 [1.06, 1.29]	1.34e-03
MPO	0.35	3393	1.17 [1.06, 1.29]	1.34e-03
AM	1.08	3393	1.17 [1.04, 1.29]	6.89e-01
OCL11	0.52	3393	1.16 [1.02, 1.33]	2.60e-02
IL-15RA	0.39	3393	1.16 [1.02, 1.33]	2.60e-02
LAP-TGF-beta-1	0.59	3393	1.15 [1.06, 1.26]	1.17e-03
NT-21	0.37	3393	1.14 [1.04, 1.25]	4.49e-03
FAS	0.49	3393	1.14 [1.04, 1.25]	4.49e-03
NT-3	0.76	3393	1.13 [1.03, 1.24]	1.12e-02
CD244	0.36	3393	1.12 [1.01, 1.23]	9.81e-02
IL-12B	0.70	3393	1.12 [1.02, 1.23]	9.81e-02
MCP-2	0.72	3393	1.12 [1.02, 1.23]	1.53e-02
MCP-1	1.50	3393	1.12 [1.02, 1.23]	1.53e-02
LDL (lab log2)	0.55	3393	1.12 [1.01, 1.24]	3.14e-02
MB	0.65	3393	1.11 [1.01, 1.22]	2.89e-02
CCL19	0.98	3393	1.11 [1.01, 1.22]	2.89e-02
FGF-5	0.53	3393	1.11 [1.00, 1.21]	4.49e-02
TNFSF14	0.68	3393	1.10 [1.01, 1.21]	2.67e-02
IL-14	0.77	3393	1.09 [0.98, 1.19]	1.23e-01
IL-13	1.72	3393	1.08 [0.98, 1.19]	1.23e-01
PARP1	0.60	3393	1.08 [0.96, 1.21]	1.99e-01
PAR-1	0.78	3393	1.08 [0.96, 1.21]	1.99e-01
MMP-7	1.81	3393	1.08 [0.97, 1.20]	1.27e-01
MCP-4	0.69	3393	1.07 [0.96, 1.17]	1.66e-01
TNFB	0.44	3393	1.07 [0.97, 1.18]	1.66e-01
IL-1-alpha	0.33	3393	1.06 [0.96, 1.16]	1.82e-01
FGF-19	0.96	3393	1.06 [0.96, 1.16]	2.27e-01
IL-15RB	1.45	3393	1.05 [0.97, 1.13]	8.71e-01
IL-17A	0.58	3393	1.05 [0.97, 1.13]	2.89e-01
TIE-2	0.23	3393	1.04 [0.96, 1.13]	3.00e-01
TNF	0.76	3393	1.04 [0.96, 1.13]	3.00e-01
AMT	0.34	3393	1.04 [0.94, 1.15]	4.69e-01
CXCL6	0.28	3393	1.03 [0.97, 1.09]	4.86e-01
CASP-8	0.07	3393	1.03 [0.94, 1.13]	4.83e-01
NEMO	0.57	3393	1.03 [0.93, 1.14]	5.50e-01
IL-17C	1.45	3393	1.03 [0.94, 1.12]	5.25e-01
MMP-1	0.76	3393	1.03 [0.94, 1.12]	5.25e-01
SELE	1.05	3393	1.02 [0.93, 1.12]	6.71e-01
ADA	0.49	3393	1.02 [0.92, 1.12]	7.18e-01
HB-EGF	0.70	3393	1.02 [0.93, 1.11]	7.26e-01
HSP-27	1.97	3393	1.02 [0.93, 1.11]	7.26e-01
CD8	0.48	3393	1.01 [0.91, 1.10]	8.70e-01
IL-4	0.20	3393	1.01 [0.92, 1.10]	9.01e-01
PSGL-1	0.70	3393	1.00 [0.91, 1.10]	9.24e-01
FRANCE	1.75	3393	1.00 [0.90, 1.10]	9.24e-01
CXCL5	1.98	3393	0.99 [0.91, 1.09]	9.26e-01
OCL4	0.75	3393	0.99 [0.91, 1.08]	9.00e-01
IL7	0.97	3393	0.99 [0.91, 1.08]	8.73e-01
CXCL1	1.36	3393	0.99 [0.91, 1.08]	8.08e-01
IL-20	0.38	3393	0.99 [0.92, 1.07]	7.74e-01
EGF	1.82	3393	0.99 [0.90, 1.08]	7.82e-01
IL-10RA	0.49	3393	0.99 [0.90, 1.08]	7.82e-01
ST1A1	1.59	3393	0.98 [0.90, 1.07]	7.02e-01
SRF	0.44	3393	0.98 [0.88, 1.08]	7.24e-01
PDGF-Subunit-B	1.53	3393	0.98 [0.89, 1.07]	6.00e-01
SIRT2	2.02	3393	0.97 [0.88, 1.07]	6.20e-01
TSLP	0.09	3393	0.97 [0.87, 1.09]	6.62e-01
AXIN1	1.48	3393	0.97 [0.88, 1.07]	5.40e-01
Dkk-1	0.89	3393	0.97 [0.88, 1.07]	5.40e-01
IL-5	0.45	3393	0.97 [0.88, 1.07]	5.61e-01
CD40-L	1.03	3393	0.97 [0.88, 1.07]	5.61e-01
GAL	2.01	3393	0.97 [0.88, 1.06]	4.50e-01
STAMPB	0.74	3393	0.97 [0.87, 1.07]	4.95e-01
IL33	1.25	3393	0.96 [0.88, 1.05]	4.24e-01
Triglycerides (lab log2)	0.72	3393	0.96 [0.87, 1.06]	4.56e-01
TRAF	0.34	3393	0.95 [0.86, 1.05]	3.07e-01
NRTN	0.39	3393	0.95 [0.86, 1.05]	3.23e-01
IL-18	0.49	3393	0.94 [0.85, 1.03]	2.04e-01
ITGB1BP2	1.67	3393	0.94 [0.85, 1.03]	1.86e-01
t-PA	0.56	3393	0.94 [0.85, 1.03]	1.89e-01
HDL (lab log2)	0.37	3393	0.93 [0.84, 1.03]	1.87e-01
IL13	0.49	3393	0.93 [0.84, 1.03]	1.75e-01
rsAMP	1.68	3393	0.92 [0.83, 1.02]	9.61e-02
IL-10RA	0.39	3393	0.92 [0.83, 1.02]	9.61e-02
LEP	1.11	3393	0.92 [0.79, 1.07]	2.75e-01
IL-16	0.16	3393	0.90 [0.79, 1.03]	1.34e-01
DNER	0.32	3393	0.89 [0.83, 0.96]	3.62e-03
TWEAK	0.40	3393	0.87 [0.81, 0.94]	7.80e-03
HB (lab log2)	0.15	3393	0.87 [0.78, 0.96]	8.11e-03
SDF1	0.48	3393	0.86 [0.78, 0.93]	4.50e-03
CFR (lab log2)	0.38	3393	0.77 [0.70, 0.86]	1.40e-06
CKD-EPI (lab log2)	0.39	3393	0.73 [0.66, 0.81]	4.22e-09




Fig 2. Multivariable adjusted linear associations in the STABILITY cohort. Cox regression analyses in the STABILITY cohort of associations between biomarkers and CV death with adjustment for baseline characteristics. Values are the same as for Fig 1. HRs and 95% CI are calculated for increase of 1 SD. Color coding according to the Boruta analysis result: green = confirmed, yellow = tentative, and red = rejected. CI, confidence interval; CV, cardiovascular; HR, hazard ratio; SD, standard deviation; STABILITY, STabilization of Atherosclerotic plaque By Initiation of darapLadIb Therapy.

<https://doi.org/10.1371/journal.pmed.1003513.g002>

Discussion

The present study investigated the associations between multiple circulating protein biomarkers, measured by immunoassays and PEA, and CV death in 2 large cohorts of optimally treated patients with chronic CHD. Employing machine learning approach, 18 biomarkers had confirmed and validated associations with CV mortality. In both cohorts, the strongest associations were found with NTproBNP and cTnT-hs, and also, the previously established independent associations with GDF-15, IL-6, and Cys-C were verified. The novel findings in the study was the identification of 13 additional proteins with an independent association to CV mortality in patients with chronic CHD, i.e., TIM-1, REN, OPG, sST2, TRAIL-R2, CA-125, BNP, HGF, SPON-1, FGF-23, CHI3L1, TNF-R1, and AM. The results indicate that myocardial strain–dysfunction–hypertrophy–fibrosis (NTproBNP, BNP, sST-2, SPON-1, and CA-125), myocyte death and apoptosis (cTnT-hs, TNF-R1, and TRAIL-R2), kidney injury (Cys-C, FGF-23, and TIM-1), hemodynamic stress, renin–angiotensin system (RAS) activation (REN and AM), oxidative stress and inflammation (GDF-15, IL-6, OPG, and CHI3L1), and angiogenesis and vascular cell proliferation (HGF) are important mechanisms associated with CV death in patients with chronic CHD (Fig 5).

The current study confirmed previous findings from our group and others on the very strong importance of the cardiac biomarkers NTproBNP and cTnT-hs for prediction of CV




Fig 3. Variable importance in the replication cohort. Boruta analysis in the LURIC cohort of the significance of variable importance for CV death in the RF analysis, including clinical variables as well as established and PEA biomarkers. Values are the same as for Fig 1. Color coding according to the Boruta analysis result: green = confirmed, yellow = tentative, and red = rejected. CV, cardiovascular; LURIC, Ludwigshafen Risk and Cardiovascular Health; PEA, proximity extension assay; RF, Random Survival Forest.

<https://doi.org/10.1371/journal.pmed.1003513.g003>




Fig 4. Multivariable adjusted linear associations in the replication cohort. Cox regression analyses in the LURIC cohort of associations between biomarkers and CV death after adjustment for baseline characteristics. Values are the same as for Fig 1. HRs and 95% CI are calculated for increase of 1 SD. Color coding according to the Boruta analysis result: green = confirmed, yellow = tentative, and red = rejected. CI, confidence interval; CV, cardiovascular; HR, hazard ratio; LURIC, Ludwigshafen Risk and Cardiovascular Health; SD, standard deviation.

<https://doi.org/10.1371/journal.pmed.1003513.g004>

Table 3. Associations between CV death and biomarkers including biomarkers with confirmed importance according to the Boruta RF analyses in both cohorts.

Biomarker	Adjusted by clinical variables ^a				Also for Cys-C+NTproBNP+cTnT-hs ^b					
	Order RF	By SD	HR	CI	C-index	p-value	HR	CI	C-index	p-value
NTproBNP	1	2.04	2.079	(1.799–2.402)	0.785	<0.001	1.779	(1.495–2.117)	0.793	<0.001
cTnT-hs	2	1.42	1.715	(1.491–1.973)	0.761	<0.001	1.266	(1.065–1.505)	0.793	0.008
GDF-15	3	0.74	1.728	(1.527–1.955)	0.765	<0.001	1.397	(1.180–1.654)	0.800	<0.001
AM	4	0.77	1.750	(1.490–2.056)	0.761	<0.001	1.352	(1.126–1.623)	0.797	0.001
OPG	5	0.45	1.488	(1.297–1.708)	0.747	<0.001	1.256	(1.087–1.452)	0.799	0.002
TIM-1	6	0.93	1.555	(1.362–1.775)	0.748	<0.001	1.294	(1.123–1.491)	0.797	<0.001
REN	7	1.09	1.501	(1.305–1.727)	0.747	<0.001	1.523	(1.329–1.745)	0.806	<0.001
Cys-C	8	0.39	1.370	(1.243–1.510)	0.747	<0.001	1.066	(0.951–1.194)	0.793	0.274
TRAIL-R2	9	0.63	1.205	(1.131–1.285)	0.740	<0.001	1.100	(0.990–1.223)	0.794	0.076
sST2	10	0.62	1.478	(1.307–1.672)	0.745	<0.001	1.250	(1.100–1.422)	0.796	<0.001
BNP	14	1.35	1.399	(1.255–1.561)	0.756	<0.001	0.860	(0.738–1.001)	0.792	0.052
HGF	17	1.31	1.259	(1.134–1.396)	0.737	<0.001	1.157	(1.031–1.299)	0.795	0.013
IL-6	18	1.24	1.478	(1.316–1.659)	0.752	<0.001	1.261	(1.110–1.432)	0.798	<0.001
CA-125	20	0.69	1.347	(1.226–1.479)	0.748	<0.001	1.101	(0.988–1.228)	0.795	0.082
SPON1	21	0.47	1.295	(1.156–1.450)	0.741	<0.001	1.072	(0.932–1.232)	0.794	0.331
TNF-R1	22	0.44	1.486	(1.307–1.689)	0.747	<0.001	1.195	(0.969–1.473)	0.794	0.096
FGF23	26	0.94	1.349	(1.237–1.472)	0.749	<0.001	1.109	(0.978–1.257)	0.795	0.107
CHI3L1	34	1.07	1.284	(1.129–1.461)	0.732	<0.001	1.110	(0.961–1.281)	0.794	0.157

The biomarkers are ordered by the position in the RF analysis in LURIC. The Cox regression and C-index results are from the replication cohort from LURIC ($n = 1,287$).

Values are NPX values (log2 scale) for the PEA biomarkers and log2 for the levels of NTproBNP, Troponin-T, Cys-C, and CRP-hs measured by conventional quantitative assays. SD, standard deviation. HR and 95% CI are calculated for increase of 1 SD. C-indices are calculated after adjustment for clinical variables as above and also after adjustment for the biomarkers NTproBNP, troponin-T, and Cys-C.

^a Clinical variable adjustment includes the variables age, sex, BMI, smoking, hypertension, diabetes mellitus, prior MI, prior PCI or CABG, prior stroke/TIA, prior PAD, and randomized treatment. ^b Adjustment also for Cys-C, NTproBNP, and cTnT-hs affects the HRs and C-indices of all variables. This leads to all C-indices having a minimal level of 0.793, i.e., the C-index for clinical variables and the 3 biomarkers Cys-C, NTproBNP, and cTnT-hs. The incremental discriminatory value of adding any additional biomarker can then be estimated by subtracting the corresponding C-index with 0.793, e.g., for GDF-15 the increment of the C-index is 0.007.

AM, adrenomedullin; BMI, body mass index; CA-125, carbohydrate antigen 125; CABG, coronary artery bypass grafting; CHI3L1, chitinase-3 like protein 1; CI, confidence interval; cTnT-hs, high-sensitivity troponin T; CV, cardiovascular; Cys-C, cystatin-C; FGF23, fibroblast growth factor 23; GDF-15, growth differentiation factor 15; HGF, hepatocyte growth factor; HR, hazard ratio; IL-6, interleukin 6; LURIC, Ludwigshafen Risk and Cardiovascular Health; MI, myocardial infarction; NPX, normalized protein expression; NTproBNP, N-terminal pro-hormone of brain natriuretic peptide; OPG, osteoprotegerin; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PEA, proximity extension assay; REN, renin; RF, Random Survival Forest; SD, standard deviation; SPON1, Spondin 1; sST2, soluble suppression of tumorigenesis 2 protein; TIA, transient ischemic attack; TIM-1, transmembrane immunoglobulin and mucin domain protein; TNF-R1, tumor necrosis factor receptor 1; TRAIL-R2, tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

<https://doi.org/10.1371/journal.pmed.1003513.t003>




Fig 5. Biomarkers and processes associated with CV death. Conceptual figure of biomarkers and processes associated with CV death in chronic CAD. CAD, coronary artery disease; CV, cardiovascular.

<https://doi.org/10.1371/journal.pmed.1003513.g005>

death in patients with CHD [6,16,21]. In the present study, these biomarkers were shown to be prognostically more important than any clinical characteristic and more important than 150 other CV and inflammatory biomarkers. NTproBNP and/or BNP and cTnT-hs are related to underlying functional myocardial disturbances, such as myocardial stretch, overload,

dysfunction, hypertrophy, and necrosis. However, no association has been identified between the levels of NTproBNP and cTnT-hs and disease development. Therefore, although associations between other biomarkers and CV death are attenuated by statistical adjustment for NTproBNP and/or cTnT-hs levels and renal dysfunction, still these associations might reflect important pathophysiological pathways.

Multiple biomarker profilings using PEA protein panels have previously been found useful for predicting chronological age using concentrations of 77 plasma proteins in 976 healthy individuals [22,23]. When the OLINK CVD I panel was used in 931 community-dwelling subjects, 7 proteins (OPG, TIM-1, GDF-15, matrix metalloproteinase-12 [MMP-12], REN, TNF ligand superfamily member 14 [TNFSF14], and growth hormone [GH]) were significantly related to the number of carotid arteries affected by plaques after adjustment for multiple testing [24]. From the same study, it was recently reported that 9 proteins (GDF-15, TIM-1, TRAIL-R2, SPON1, MMP-12, follistatin [FS], soluble urokinase-type plasminogen activator surface receptor [sU-PAR], OPG, and sST2) were associated with the development of heart failure [25]. It is noteworthy that 4 of these 9 proteins (GDF-15, TIM-1, OPG, and sST2) were identified and validated in the present study and that 4 others (TRAIL-R2, SPON1, MMP-12, and sU-PAR) were significant in the STABILITY cohort of the present study. The OLINK CVD I panel was also used in 847 patients with acute MI in whom the levels of GDF-15 and TRAIL-R2 were independently associated with all-cause mortality during 7 years follow-up in accordance with the present findings in the STABILITY study [26].

In 2016, a multimarker tool based on estimation of protein levels by the Somalogic modified aptamer technology was used to identify the 4-year risk of MI, stroke, heart failure, and all-cause death in 1 derivation and 1 replication cohort of patients with chronic CAD [27]. This study identified a 9-protein model providing a c-statistic of 0.71 in the replication sample, in which troponin was the only biomarker in common with the present findings. Based on the Luminex xMAP platform, another multimarker model to identify the risk of CV death, MI, or stroke was developed in a derivation cohort of 649 and replication cohort 278 patients. This model included the 4 biomarkers NTproBNP, TIM-1, osteopontin, and tissue inhibitor of metalloproteinase-1 (TIMP-1), which had a c-index of 0.79. Interestingly, NTproBNP and TIM-1 are the same markers as identified in the present study and osteopontin protein may reflect the same processes as OPG [28]. The lack of complete replication of identified markers between the studies might relate to many factors, e.g., differences in measured biomarkers, handling and age of biosamples, assay technologies, endpoints, adjustments, patient populations, treatments, and follow-up.

After the specific cardiac markers, GDF-15, a marker of oxidative stress, cellular aging, and inflammatory activity, showed the strongest association with CV death. The independent prognostic value GDF-15 [5,15,29] concerning total and CV mortality has been documented previously from the STABILITY trial as well as in several other studies. Several other proteins reflecting inflammatory activity (IL-6, CHI3L1, TIM-1, and OPG) were also significantly associated with the risk of CV death in both the present cohorts. Independent associations between IL-6 [17] and CV mortality have previously been shown in this and other studies. Also, CHI3L1 [30] and TIM-1 [31] have been found associated with the development of coronary atherosclerosis. OPG, a member of the tumor necrosis factor receptor superfamily, has pleiotropic effects on bone metabolism, endocrine functions, and vascular inflammation [32,33]. It is expressed by inflammatory stimuli, during acute MI and heart failure, and OPG plasma levels are related to outcomes in patients with these conditions [34–36]. The recently reported simultaneous reduction of inflammatory activity, e.g., as documented by simultaneous reduction of IL-6 levels and ischemic events by treatment with the anti-inflammatory agents canakinumab [37] and colchicine [38], further supports inflammatory activity as a major pathophysiological mechanism in CHD [39].

Chronic kidney disease is a well-established risk factor for CV death. Accordingly, the level of Cys-C, which reflects glomerular filtration rate, has repeatedly been demonstrated to be associated with CV events and death in patients with CHD. The renal hormone renin is a pivotal component of the RAS, which plays a key role in the maintenance of blood pressure and electrolyte-volume homeostasis. The RAS is activated in hypertension and heart failure, and reduction of its activity has become the basis for both prevention and treatment of these conditions [1,2]. AM [40] and CA-125 [41] are indicators of fluid overload and congestion and probably thereby indicators of outcome in CAD. FGF23, a hormone for regulation of phosphate hemostasis and the renin-angiotensin-aldosterone system, is an indicator of both renal and myocardial dysfunction and is associated with left ventricular hypertrophy and clinical outcomes [42]. An animal study has demonstrated *Spon1* mRNA expression in different vascular tissues with the same expression in kidney and heart [43]. In this rat model, the *Spon1* gene was also identified as a novel candidate gene for hypertension. In previous human studies, SPON1 has turned out to be an indicator of myocardial and renal dysfunction [25]. We also confirmed an independent association between TIM-1, a modulator of the T cell-mediated immune response, and CV outcomes [44–46]. Moreover, recently, an anti-TIM-1 antibody was shown to attenuate atherosclerosis development [31]. The identification of all these markers of CV-renal dysfunction as independent risk indicators in the current cohorts of chronic CHD is impressive not least after adjustment for the established and strong biomarkers of renal (Cys-C) and cardiac function (NTproBNP and cTnT-hs) [47].

In the present study, sST2 emerged as an independent biomarker contributing to risk stratification for CV death. ST2 is the receptor for interleukin-33, a cytokine with antihypertrophic and antifibrotic effects on the myocardium. Serum levels of the soluble form of sST2 is a biomarker for myocardial strain and is well established to provide prognostic information in patients with heart failure [48] but also in patients with chronic CHD [49], acute coronary syndrome [50], and in population-based cohorts (Dallas Heart) [51]. The prognostic importance of sST2 in the LURIC cohort has been shown earlier by using a conventional immunoassay, which strengthens the current findings with PEA technology [52].

HGF also appeared as a factor that significantly contributed to the identification of the risk of CV death in the current study. HGF has pleiotropic cell functions including angiogenesis, anti-apoptosis, proliferation, and differentiation. Based on high levels in the early phase of MI and in heart failure, HGF has been suggested as a prognostic and diagnostic biomarker of CV disease [53]. HGF gene therapy has also been used in the treatment of ischemic heart disease and for tissue regeneration [54]. In accordance with our findings, the level of HGF has previously been found to be independently associated with the progression of atherosclerosis and clinical events in patients with CHD and heart failure and with long-term mortality in the general population [55–59].

Finally, TNF-R1 and TRAIL-R2 are members of the TNF receptor superfamily and involved in the processes of apoptosis. Probably, these processes are activated by several of the other mechanisms associated with a raised risk for CV death and their incremental importance most likely limited [25,60].

Limitations and strengths

Although being a large trial with global recruitment, the STABILITY cohort might not be fully representative for all patients with chronic CHD. For example, less than 20% of patients were women, smokers, or had prior multivessel disease. Also, the LURIC observational cohort has limitations, for example, because of recruitment in association with a coronary angiogram and a lack of systematic follow-up concerning secondary preventive treatment and nonfatal events.

Therefore, some biomarkers appearing to have prognostic importance in one setting might not be possible to verify because of the differences in design and size of the studies. However, the differences in design might also be considered an advantage when searching for more robust prognostic biomarkers with relevance in the broad real-life patient population. In the LURIC trial, the associations using 4 years or 12 years follow-up were similar, although with weaker significances at 4 years because of fewer events. Evaluation of shorter time follow-up was avoided because of low event rates and thereby too low statistical power for reliable multivariate evaluation of multiple biomarkers. Some biomarkers had low availability, making them impossible to evaluate in this setting.

Implication and next steps

The employed multiplex PEA methodology provides a profile of the relative protein concentrations, which is appropriate for screening of the most useful proteins to include in a multiplex assay. However, for final evaluation of the usefulness of protein profiling, a multiplex assay allowing simultaneous and precise quantification across the complete dynamic range of all included proteins will be needed.

Conclusions

In patients with chronic CHD, 18 out of 157 circulating biomarkers had internally confirmed and externally validated independent significant associations with CV death. The results indicate that myocardial strain–dysfunction–hypertrophy–fibrosis (NTproBNP, BNP, sST2, SPON1, and CA-125), myocyte death and apoptosis (cTnT-hs, TNF-R1, and Trail-R2), kidney injury (Cys-C, FGF-23, and TIM-1), hemodynamic stress, RAS activation (REN and AM), oxidative stress (GDF-15 and OPG), vascular inflammation and immune modulation (IL-6 and CHI3L1), and angiogenesis and vascular cell proliferation (HGF) are important mechanisms associated with CV death in patients with chronic CHD (Fig 5). Profiles of levels of multiple plasma proteins can be useful for the identification of different pathophysiologic pathways associated with an increased risk of CV death in patients with chronic CHD. Measurements of these profiles and their pathways might be useful for the identification of new treatment targets and balancing different treatments in patients with chronic CHD.

Supporting information

S1 STROBE Checklist. STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.

(DOCX)

S1 Text. Statistical analysis plan.

(PDF)

S1 Table. Proteins included on the Olink CVD I and Inflammation panels.

(PDF)

S2 Table. PEA biomarker NPX values. (A) Data availability in all 4,127 patients in the STABILITY cohort. (B) Data availability in all 1,331 patients in the LURIC cohort. LURIC, Ludwigshafen Risk and Cardiovascular Health; NPX, normalized protein expression; PEA, proximity extension assay; STABILITY, STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY.

(PDF)

S3 Table. Baseline characteristics in the randomly selected subcohort and in all patients in the STABILITY trial. STABILITY, STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY.

(PDF)

S4 Table. (A) Reproducibility of biomarkers determined in both the CVD1 and Inflammation OLINK PEA panels. (B) Comparisons between biomarkers associations with CV death when using measurements with conventional (lab log₂) and PEA assays (NPX) as evaluated by univariate Cox regression analyses. CV, cardiovascular; NPX, normalized protein expression; PEA, proximity extension assay.

(PDF)

S5 Table. Spearman correlation between the NPX values of relevant PEA biomarkers (rows with any correlation >0.29) and the logarithmic transformation of the ng/L levels of established biomarkers (including only the random cohort in the STABILITY cohort).

NPX, normalized protein expression; PEA, proximity extension assay; STABILITY, STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY.

(PDF)

S6 Table. PEA biomarker NPX values in patients with and without CV death in (A) the STABILITY cohort and (B) the LURIC cohort (numbers are percentiles 25th/50th/75th).

CV, cardiovascular; LURIC, Ludwigshafen Risk and Cardiovascular Health; NPX, normalized protein expression; PEA, proximity extension assay; STABILITY, STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY.

(PDF)

S1 Fig. Random Forest analysis in (A) the STABILITY cohort and (B) the LURIC cohort of prognostic variables for CV death including clinical variables as well as established and PEA biomarkers.

Each estimate of variable importance is colored by the Boruta analysis result. CV, cardiovascular; LURIC, Ludwigshafen Risk and Cardiovascular Health; PEA, proximity extension assay; RF, Random Survival Forest; STABILITY, STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY.

(PDF)

S2 Fig. Multivariable unadjusted linear associations by Cox regression analyses in (A) the LURIC cohort and (B) the STABILITY cohort of associations between biomarkers and CV death. Values are the same as for Fig 1. HR and 95% CI are calculated for increase of 1 SD.

Color coding according to the Boruta analysis result: green = confirmed, yellow = tentative, and red = rejected. Variables colored white were not included in the Boruta analysis. CI, confidence interval; CV, cardiovascular; HR, hazard ratio; LURIC, Ludwigshafen Risk and Cardiovascular Health; PEA, proximity extension assay; SD, standard deviation; STABILITY, STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY.

(PDF)

Author Contributions

Conceptualization: Lars Wallentin, Niclas Eriksson, Agneta Siegbahn.

Data curation: Mikael Åberg.

Formal analysis: Lars Wallentin, Niclas Eriksson, Agneta Siegbahn.

Funding acquisition: Lars Wallentin.

Investigation: Maciej Olszowka, Tanja B. Grammer, Emil Hagström, Claes Held, Marcus E. Kleber, Wolfgang Koenig, Winfried März, Ralph A. H. Stewart, Harvey D. White, Mikael Åberg.

Project administration: Lars Wallentin.

Supervision: Lars Wallentin.

Writing – original draft: Lars Wallentin.

Writing – review & editing: Niclas Eriksson, Maciej Olszowka, Tanja B. Grammer, Emil Hagström, Claes Held, Marcus E. Kleber, Wolfgang Koenig, Winfried März, Ralph A. H. Stewart, Harvey D. White, Mikael Åberg, Agneta Siegbahn.

References

1. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2012; 60:2564–603. <https://doi.org/10.1016/j.jacc.2012.07.012> PMID: 23182124
2. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020; 41:407–77.
3. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. *N Engl J Med*. 2020.
4. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2016; 37:267–315. <https://doi.org/10.1093/eurheartj/ehv320> PMID: 26320110
5. Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. *Clin Chem*. 2017; 63:140–51. <https://doi.org/10.1373/clinchem.2016.255174> PMID: 28062617
6. Omland T, White HD. State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. *Clin Chem*. 2017; 63:165–76. <https://doi.org/10.1373/clinchem.2016.255190> PMID: 27815307
7. Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. *Circulation*. 2017; 135:e1054–e91. <https://doi.org/10.1161/CIR.0000000000000490> PMID: 28446515
8. Goff DCJ, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014; 129:S49–73. <https://doi.org/10.1161/01.cir.0000437741.48606.98> PMID: 24222018
9. Assarsson E, Lundberg M, Holmquist G, Björkstén J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. *PLoS ONE*. 2014; 9:e95192. <https://doi.org/10.1371/journal.pone.0095192> PMID: 24755770
10. Ebai T, Kamali-Moghaddam M, Landegren U. Parallel protein detection by solid-phase proximity ligation assay with real-time PCR or sequencing. *Curr Protoc Mol Biol*. 2015; 109:20 10 1–25. <https://doi.org/10.1002/0471142727.mb2010s109> PMID: 25559104
11. Darmanis S, Nong RY, Vanelid J, Siegbahn A, Ericsson O, Fredriksson S, et al. ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing. *PLoS ONE*. 2011; 6:e25583. <https://doi.org/10.1371/journal.pone.0025583> PMID: 21980495
12. White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadlb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. *Am Heart J*. 2010; 160:655–61. <https://doi.org/10.1016/j.ahj.2010.07.006> PMID: 20934559

13. White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, et al. Darapladib for preventing ischemic events in stable coronary heart disease. *N Engl J Med*. 2014; 370:1702–11. <https://doi.org/10.1056/NEJMoa1315878> PMID: 24678955
14. Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, et al. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. *J Am Heart Assoc*. 2016; 5:e003407. <https://doi.org/10.1161/JAHA.116.003407> PMID: 27329448
15. Hagström E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, et al. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. *Clin Chem*. 2017; 63:325–33. <https://doi.org/10.1373/clinchem.2016.260570> PMID: 27811204
16. Lindholm D, Lindbäck J, Armstrong PW, Budaj A, Cannon CP, Granger CB, et al. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. *J Am Coll Cardiol*. 2017; 70:813–26. <https://doi.org/10.1016/j.jacc.2017.06.030> PMID: 28797349
17. Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, et al. Inflammatory biomarkers Interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease—experiences from the STABILITY trial. *J Am Heart Assoc*. 2017; 6:e005077. <https://doi.org/10.1161/JAHA.116.005077> PMID: 29066452
18. Kursu MB. Robustness of Random Forest-based gene selection methods. *BMC Bioinformatics*. 2014; 15:8. <https://doi.org/10.1186/1471-2105-15-8> PMID: 24410865
19. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2016. Available from: <https://www.R-project.org/>
20. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *J Stat Softw*. 2011; 45:1–67.
21. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med*. 2008; 358:2107–16. <https://doi.org/10.1056/NEJMoa0707064> PMID: 18480203
22. Enroth S, Bosdotter Enroth S, Johansson Å, Gyllensten U. Effect of genetic and environmental factors on protein biomarkers for common non-communicable disease and use of personally normalized plasma protein profiles (PNPPP). *Biomarkers*. 2015; 20:355–64. <https://doi.org/10.3109/1354750X.2015.1093546> PMID: 26551787
23. Enroth S, Enroth SB, Johansson Å, Gyllensten U. Protein profiling reveals consequences of lifestyle choices on predicted biological aging. *Sci Rep*. 2015; 5:17282. <https://doi.org/10.1038/srep17282> PMID: 26619799
24. Lind L, Ärnliöv J, Lindahl B, Siegbahn A, Sundström J, Ingelsson E. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. *Atherosclerosis*. 2015; 242:205–10. <https://doi.org/10.1016/j.atherosclerosis.2015.07.023> PMID: 26204497
25. Stenemo M, Nowak C, Byberg L, Sundström J, Giedraitis V, Lind L, et al. Circulating proteins as predictors of incident heart failure in the elderly. *Eur J Heart Fail*. 2018; 20:55–62. <https://doi.org/10.1002/ejhf.980> PMID: 28967680
26. Skau E, Henriksen E, Wagner P, Hedberg P, Siegbahn A, Leppert J. GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. *Eur J Prev Cardiol*. 2017; 24:1576–83. <https://doi.org/10.1177/2047487317725017> PMID: 28762762
27. Ganz P, Heidecker B, Hveem K, Jonasson C, Kato S, Segal MR, et al. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. *JAMA*. 2016; 315:2532–41. <https://doi.org/10.1001/jama.2016.5951> PMID: 27327800
28. McCarthy CP, van Kimmenade RRJ, Gaggin HK, Simon ML, Ibrahim NE, Gandhi P, et al. Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study). *Am J Cardiol*. 2017; 120:25–32. <https://doi.org/10.1016/j.amjcard.2017.03.265> PMID: 28487034
29. Wallentin L, Zethelius B, Berglund L, Eggers KM, Lind L, Lindahl B, et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. *PLoS ONE*. 2013; 8:e78797. <https://doi.org/10.1371/journal.pone.0078797> PMID: 24312445
30. Schroder J, Jakobsen JC, Winkel P, Hilden J, Jensen GB, Sajadieh A, et al. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease. *J Am Heart Assoc*. 2020; 9:e014634. <https://doi.org/10.1161/JAHA.119.014634> PMID: 32114892
31. Hosseini H, Yi L, Kanellakis P, Cao A, Tay C, Peter K, et al. Anti-TIM-1 Monoclonal Antibody (RMT1-10) Attenuates Atherosclerosis By Expanding IgM-producing B1a Cells. *J Am Heart Assoc*. 2018; 7:e008447. <https://doi.org/10.1161/JAHA.117.008447> PMID: 29936416

32. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. *Arthritis Res Ther*. 2007(9 Suppl): 1, S1.
33. Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Aukrust P, Becker RC, et al. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. *J Am Heart Assoc*. 2018; 7:e007009. <https://doi.org/10.1161/JAHA.117.007009> PMID: 29330256
34. Røysland R, Bonaca MP, Omland T, Sabatine M, Murphy SA, Scirica BM, et al. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. *Heart*. 2012; 98:786–91. <https://doi.org/10.1136/heartjnl-2011-301260> PMID: 22373720
35. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. *J Am Coll Cardiol*. 2008; 51:627–33. <https://doi.org/10.1016/j.jacc.2007.09.058> PMID: 18261681
36. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. *J Am Coll Cardiol*. 2004; 44:1970–6. <https://doi.org/10.1016/j.jacc.2004.06.076> PMID: 15542278
37. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J*. 2018; 39:3499–507. <https://doi.org/10.1093/eurheartj/ehy310> PMID: 30165610
38. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med*. 2019; 381:2497–505. <https://doi.org/10.1056/NEJMoa1912388> PMID: 31733140
39. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med*. 2017; 377:1119–31. <https://doi.org/10.1056/NEJMoa1707914> PMID: 28845751
40. Tonkin AM, Blankenberg S, Kirby A, Zeller T, Colquhoun DM, Funke-Kaiser A, et al. Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. *Int J Cardiol*. 2015; 201:499–507. <https://doi.org/10.1016/j.ijcard.2015.07.080> PMID: 26318511
41. Falcão F, de Oliveira FRA, da Silva M, Sobral Filho DC. Carbohydrate antigen 125: a promising tool for risk stratification in heart diseases. *Biomark Med*. 2018; 12:367–81. <https://doi.org/10.2217/bmm-2017-0452> PMID: 29425051
42. Qin Z, Liu X, Song M, Zhou Q, Yu J, Zhou B, et al. Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies. *Atherosclerosis*. 2017; 261:1–11. <https://doi.org/10.1016/j.atherosclerosis.2017.03.042> PMID: 28411494
43. Clemitson JR, Dixon RJ, Haines S, Bingham AJ, Patel BR, Hall L, et al. Genetic dissection of a blood pressure quantitative trait locus on rat chromosome 1 and gene expression analysis identifies SPON1 as a novel candidate hypertension gene. *Circ Res*. 2007; 100:992–9. <https://doi.org/10.1161/01.RES.0000261961.41889.9c> PMID: 17332427
44. Carlsson AC, Larsson A, Helmersson-Karlqvist J, Lind L, Ingelsson E, Larsson TE, et al. Urinary kidney injury molecule-1 and the risk of cardiovascular mortality in elderly men. *Clin J Am Soc Nephrol*. 2014; 9:1393–401. <https://doi.org/10.2215/CJN.11901113> PMID: 24923577
45. Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X, et al. Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study. *Clin J Am Soc Nephrol*. 2017; 12:761–71. <https://doi.org/10.2215/CJN.08560816> PMID: 28254771
46. de Souza AJ, Oriss TB, O'Malley KJ, Ray A, Kane LP. T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. *Proc Natl Acad Sci U S A*. 2005; 102:17113–8. <https://doi.org/10.1073/pnas.0508643102> PMID: 16284246
47. Volpe M, Unger T. Plasma renin and cardiovascular risk: what is the evidence for an association? *Cardiology*. 2013; 125:50–9. <https://doi.org/10.1159/000348365> PMID: 23636010
48. Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. *Eur J Heart Fail*. 2017; 19:1001–10. <https://doi.org/10.1002/ehfj.749> PMID: 28133908
49. Pfetsch V, Sanin V, Jaensch A, Dallmeier D, Mons U, Brenner H, et al. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study. *Cardiovasc Drugs Ther*. 2017; 31:167–77. <https://doi.org/10.1007/s10557-017-6718-1> PMID: 28283847
50. Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. *Am Heart J*. 2010; 159:788–94. <https://doi.org/10.1016/j.ahj.2010.02.022> PMID: 20435187

51. Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. *Clin Chem*. 2013; 59:536–46. <https://doi.org/10.1373/clinchem.2012.191106> PMID: 23220272
52. Dieplinger B, Egger M, Haltmayer M, Kleber ME, Scharnagl H, Silbernagel G, et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. *Clin Chem*. 2014; 60:530–40. <https://doi.org/10.1373/clinchem.2013.209858> PMID: 24401186
53. Madonna R, Cevik C, Nasser M, De Caterina R. Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration. *Thromb Haemost*. 2012; 107:656–61. <https://doi.org/10.1160/TH11-10-0711> PMID: 22318499
54. Wang LS, Wang H, Zhang QL, Yang ZJ, Kong FX, Wu CT. Hepatocyte Growth Factor Gene Therapy for Ischemic Diseases. *Hum Gene Ther*. 2018; 29:413–23. <https://doi.org/10.1089/hum.2017.217> PMID: 29409352
55. Susen S, Sautière K, Mouquet F, Cuilleret F, Chmait A, McFadden EP, et al. Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization. *Eur Heart J*. 2005; 26:2387–95. <https://doi.org/10.1093/eurheartj/ehi436> PMID: 16105849
56. Rychli K, Richter B, Hohensinner PJ, Kariem Mahdy A, Neuhold S, Zorn G, et al. Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. *Heart*. 2011; 97:1158–63. <https://doi.org/10.1136/hrt.2010.220228> PMID: 21572126
57. Bell EJ, Decker PA, Tsai MY, Pankow JS, Hanson NQ, Wassel CL, et al. Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2018; 272:162–7. <https://doi.org/10.1016/j.atherosclerosis.2018.03.040> PMID: 29609131
58. Santalahti K, Havulinna A, Maksimow M, Zeller T, Blankenberg S, Vehtari A, et al. Plasma levels of hepatocyte growth factor and placental growth factor predict mortality in a general population: a prospective cohort study. *J Intern Med*. 2017; 282:340–52. <https://doi.org/10.1111/joim.12648> PMID: 28682476
59. Pérez-Calvo JI, Morales-Rull JL, Gimeno-Orna JA, Laserra-Díaz P, Josa-Laorden C, Puente-Lanzarote JJ, et al. Usefulness of the Hepatocyte Growth Factor as a Predictor of Mortality in Patients Hospitalized With Acute Heart Failure Regardless of Ejection Fraction. *Am J Cardiol*. 2016; 118:543–9. <https://doi.org/10.1016/j.amjcard.2016.05.048> PMID: 27338207
60. Carlsson AC, Ruge T, Kjølner E, Hilden J, Kolmos HJ, Sajadieh A, et al. 10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial Substudy. *J Am Heart Assoc*. 2018; 7:e008299. <https://doi.org/10.1161/JAHA.117.008299> PMID: 29686027